Back
Non-Moderated Poster Abstract
Eposter Presentation
https://storage.unitedwebnetwork.com/files/1237/9f691cca440a72ddcfa1b4cedbddd1d6.pdf
Accept format: PDF. The file size should not be more than 5MB
https://storage.unitedwebnetwork.com/files/1237/db9f026d6ed7cba2bf9dfe2caaf530cf.jpg
Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB
 
Submitted
Abstract
Is diabetes mellitus associated with clinical outcomes in aging males treated with minimally invasive surgical therapies? A real world study from TriNetX global collaborative networks
Non-Moderated Poster Abstract
Clinical Research
Benign Prostate Hyperplasia and Male Lower Urinary Tract Symptoms: Minimally Invasive Surgery
Author's Information
2
No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.
Taiwan
Chih-Hao Hsu jerry7010930@gmail.com Wan Fang Hospital Department of Urology Taipei Taiwan *
Yu-Xiang Yang 113279@w.tmu.edu.tw Wan Fang Hospital Department of Urology Taipei Taiwan -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract Content
Previous clinical data indicated that diabetes mellitus (DM) was associated with poorer outcomes in patients treated with traditional transurethral resection of the prostate (TUR-P). Minimally invasive surgical therapies (MISTs) such as UroLift and Rezūm have recently emerged as alternative treatments for benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTSs) and may be more suitable for patients with multiple comorbidities. Therefore, this study aimed to assess the LUTSs and clinical outcomes between patients with diabetes mellitus (DM) and non-diabetic (non-DM) patients who underwent UroLift and Rezūm.
This retrospective cohort study utilized the TriNetx database to analyze data from a total of 5158 patients with persistent LUTSs who underwent UroLift or Rezūm for benign prostate enlargement (BPE). Patients were divided into DM and non-DM groups. To mitigate potential bias from baseline characteristics, we employed 1:1 propensity score (PS) matched analysis based on significant prognostic variables to establish comparable treatment groups.
Postoperatively, the DM group exhibited a slightly higher risk of urinary tract infection (UTI) (Hazard Ratio [HR] 1.14, 95% Confidence Interval [CI] 1.013–1.293) compared to the non-DM group. However, there were no significant differences observed in acute urinary retention (AUR) (HR 0.90, 95% CI 0.771–1.069), ejaculatory function (HR 1.146, 95% CI 0.69–1.904), sexual dysfunction (HR 0.914, 95% CI 0.76–1.099), reintervention rate (HR 1.02, 95% CI 0.844–1.255), or postoperative medication-free rate (HR 0.98, 95% CI 0.77–1.256) between the two groups.
Patients with DM had a higher rate of UTI after undergoing UroLift or Rezūm. However, no significant differences were found in AUR, reintervention rate, sexual dysfunction rate, or postoperative medication rate compared to non-DM patients. Considering previous studies that demonstrated poorer outcomes in DM patients treated with TUR-P, MISTs may represent a viable alternative treatment option for BPH-related LUTSs in patients with diabetes.
 
 
 
 
 
 
 
 
 
 
 
1634
 
Presentation Details
 
 
 
0